Sydney, Australia, 28 January 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announces a clinical development update on its PD1-Vaxx cancer immunotherapy. PD1- Vaxx will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, accounting for around 80% of cases. The study is planned to commence in 2020 and is to be conducted at up to 6 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.
Highlights:
• GMP manufacturing including sterile fill and finish complete
• All preclinical toxicology studies complete allowing confirmation of clinical dose levels
• Toxicology studies confirm PD1-Vaxx generates high levels of antibodies
For further information, please download the attached PDF
Download this document
